Abstract

Phosphodiesterase (PDE) inhibitors are potent cardiotonic agents. The hemodynamic effects of amrinone, the first compound of this new class of drugs to be approved for clinical investigation were reported a decade ago [1]. Since then, many other PDE inhibitors have been introduced: some of them are now available for clinical use, depending on the countries: amrinone,milrinone, enoximone. Other PDE inhibitors are still under clinical investigation. Although they have mainly been reported in the treatment of severe congestive heart failure patients, they have also been successfully used in the management of various forms of acute circulatory failure.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.